SUBSCRIBE

Breaking News on Global Pharmaceutical Technology & Manufacturing

Headlines > All Ingredients News

Patheon: Irix deal about US and Canadian customer demand for local APIs; all staff to be retained

05-Mar-2015 - Irix Pharmaceuticals will cater for North American customers’ desire for local supply according to Patheon, which says it plans to retain the API firm’s 180 staff.

Hundreds of API suppliers with plants in new Indian state Telangana need to update EDQM

04-Mar-2015 - As many as 450 API and intermediate suppliers in India's newest State - Telangana – need to log their changed addresses with the EDQM before August.

Patheon has bought hard-to-make API specialist Irix Pharmaceuticals

04-Mar-2015 - Patheon has bought hard-to-manufacture active pharmaceutical ingredient (API) specialist, Irix Pharmaceuticals.

US defence cuts an opportunity for generics firm KVK Tech

04-Mar-2015 - US fighter jet firm Lockheed Martin has agreed to sell a satellite production plant in Newtown, Pennsylvania to drugmaker KVK-Tech.

AZ spins out antibiotics R&D biz to focus on key pipelines

04-Mar-2015 - AstraZeneca will spend $40m spinning out its antibiotics R&D business into a separate subsidiary, saying the move will let it focus on its core disease areas.

Apax's proposed Azelis takeover backed by unions

25-Feb-2015 - Apax Partners says workers' unions have backed its plan to buy a controlling stake in chemical distributor Azelis from fellow private equity firm 3i.

Shire steps further into rare diseases with $70m acquisition

25-Feb-2015 - Shire has acquired privately-held Meritage for an upfront fee of $70m and additional contingent payments based on the achievement of development and regulatory milestones. 

Assembly line could cut cost of HIV drug API production say German researchers

24-Feb-2015 - The HIV drug API efaverinz could be made faster and more cheaply using continuous manufacturing according to the German team behind a new ‘assembly line’ production method.

Facility already supplying Granules' JV partner Ajinomoto Omnichem with validation batches

Granules predicts US and EMA approval for new API plant in two years

23-Feb-2015 - An API and intermediates plant set up by Granules India and Ajinomoto Omnichem is a step closer to opening after an offical inauguration ceremony last week. 

Rebooting HAL part of Indian plans to boost API capacity and cut relaince on China

19-Feb-2015 - The Indian Government wants to build API production capacity and revive state run manufacturer Hindustan Antibiotics to cut reliance on Chinese imports.

IPEC raises concerns over FDA guidance related to inactive ingredients

19-Feb-2015 - The International Pharmaceutical Excipients Council of the Americas (IPEC) is raising concerns with the US FDA over ANDA (abbreviated new drug application) guidance related to excipients.

SGS rolls out latest Ph.Eur. amino acid impurities testing method at German lab

18-Feb-2015 - SGS will soon be able to test up to 30 batches of amino acids for impurities per month after adding new analytical methods to those offered at its laboratory in Taunusstein, Germany.

PE-backed Laurus Labs sets up US drug ingredients business

16-Feb-2015 - Warburg Pincus-backed HIV drug ingredient firm Laurus Labs has set up a US presence and development facility in a bid to win more North American customers.

Enteris plans to beat established API CMOs on lead times

16-Feb-2015 - Enteris Biopharma says it can compete with established API CMOs by offering shorter lead times and greater flexibility.

AMRI looks to close API facility in Wales as part of network realignment

12-Feb-2015 - AMRI has announced plans to close an API development and manufacturing plant in Wales, UK, after efforts to establish it as a conduit between the US and Europe were deemed unsuccessful.

Penn is mightily pleased with safety record

10-Feb-2015 - Banishing kettles, 'Gemba walks' and encouraging employees to report near misses have helped Penn Pharma to remain accident free at its high potency compound manufacturing facility in Wales.

Cambrex: ‘Either we invest now or turn away API business”

09-Feb-2015 - Ongoing demand for large-scale APIs combined with high capacity utilization has driven Cambrex Corporation to allot up to $85m (€70m) for manufacturing expansion in 2015.

Dispatches from InformEx

US-EU trade agreement not likely until 2017, SOCMA says

09-Feb-2015 - Pharmaceutical and chemical manufacturers may have to wait until 2017 to see the benefits of the Transatlantic Trade and Investment Partnership, VP of SOCMA (Society of Chemical Manufacturers and Affiliates) told attendees at InformEx in New Orleans.

Drug excipients industry meets in Nice

05-Feb-2015 -   [View the story "Nice work if you can get it: Excipient firms on the Côte d'Azur" on Storify]

Vertellus buys antiretroviral API reagent plant from Dow

04-Feb-2015 - Specialty chemicals firm Vertellus will continue to supply antiretroviral drugmakers sodium borohydride following its takeover of a Dow plant in Washington State.

ScinoPharm: profits fall on higher costs, an idle plant and lower Qsymia sales

03-Feb-2015 - ScinoPharm was hurt by weak US demand for the weight loss pill Qsymia, higher raw material prices and costs associated with its still unapproved plant in China in 2014.

Analyst: Pfizer's withdrawal from Repligen deal "not smart" amid growing Big Pharma interest in SMA

03-Feb-2015 - Pfizer must act fast to convince investors it can compete with Roche and Biogen Idec for a share of the spinal muscular atrophy (SMA) market says analyst.

Sun, spots: US FTC says Ranbaxy must sell acne drug to Torrent before Sun takeover

02-Feb-2015 - Ranbaxy must sell its acne drug minocycline to Torrent Pharmaceuticals and support the firm while it gains regulatory approval for its API supplier before the US Federal Trade Commission will allow Sun Pharmaceutical Industries to complete its $4bn takeover.

Provectus seeking Indian PV-10 API patent and says it is “more than a match” for skin cancer competitors

29-Jan-2015 - Provectus Biopharmacetuicals is seeking an Indian patent and partner for PV-10 and says it is 'more than a match' for skin cancer competitors like Merck & Co and Bristol-Myers Squibb.

Johnson Matthey posts higher Q3 API profits; Pfizer patent spat continues

28-Jan-2015 - Johnson Matthey saw demand for ADHD APIs increase in the third quarter, while sales of its pain management ingredients and bulk opiates declined.

Spotlight

Third time's a charm: Pfizer to buy Hospira for $17bn
breaking news

Third time's a charm: Pfizer to buy Hospira for $17bn

Pfizer has entered into a definitive merger agreement to buy Hospira for $17bn.

Vertellus buys antiretroviral API reagent plant from Dow

Vertellus buys antiretroviral API reagent plant from Dow

Specialty chemicals firm Vertellus will continue to supply antiretroviral drugmakers sodium borohydride following its takeover of a...

ScinoPharm: profits fall on higher costs, an idle plant and lower Qsymia sales

ScinoPharm: profits fall on higher costs, an idle plant and lower Qsymia sales

ScinoPharm was hurt by weak US demand for the weight loss pill Qsymia, higher raw material prices...

Analyst: Pfizer's withdrawal from Repligen deal "not smart" amid growing Big Pharma interest in SMA

Analyst: Pfizer's withdrawal from Repligen deal "not smart" amid growing Big Pharma interest in SMA

Pfizer must act fast to convince investors it can compete with Roche and Biogen Idec for a...

MUGAS-funded Tamiflu analysis included fewer studies than Cochrane review

MUGAS-funded Tamiflu analysis included fewer studies than Cochrane review

Researchers claiming Tamiflu cuts flu symptom duration and hospitalisations analysed less than half as many studies as...